Please login to the form below
DLBCL
This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.
EMA starts review of MorphoSys’ tafasitamab for lymphoma
The US regulator accepted MorphoSus and partner Incyte’s marketing application for tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) – including DLBCL arising from low ... MIND study in previously-untreated
Latest news
-
IMV preps pivotal trials for ovarian cancer T cell therapy
B-cell lymphoma (DLBCL) and another spanning multiple solid tumour types.
-
EU grants conditional approval to Roche's lymphoma drug Polivy
The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL
-
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and CLL. ... MorphoSys has already filed tafasitamab with the FDA, as a treatment for patients with r/r DLBCL, and expects a decision by mid-2020.
-
Armed with new data, BMS plans filings for Celgene CAR-T liso-cel
acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL). ... Meanwhile, in the same period Yescarta brought in $183m from its use in DLBCL and other B-cell lymphoma types.
-
Gracell reports impressive data with one-day CAR-T for leukaemia
Kymriah is approved for B-ALL as well as diffuse large B-cell lymphoma (DLBCL) – a form of non-Hodgkin’s lymphoma – and made just over $100m in sales in the ... Meanwhile, Gilead reported $216m in first-half sales from DLBCL and another NHL variant
More from news
Approximately 9 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with
-
Cancer immunotherapy: What's on the horizon?
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
-
Deal Watch January 2018
pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics
-
Pharma deals in April 2015
its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
-
Current development and marketing of biosimilar monoclonal antibodies in Latin America
Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer
- ASCO: Bavencio boosts survival post-chemo in bladder cancer
- Policy and public health COVID-19 by the numbers
- The key to maintaining business continuity
- Are biobetters a market access opportunity?
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
- Why we need to improve diverse representation in clinical trials
- Diversity in clinical trials: The powerful need to improve it! “One size fits all” is rapidly becoming an outdated concept in modern-day life, and medical research is no exception. Without...
Quick links
Infographics
